Umedaptanib pegol

TOKYO--( BUSINESS WIRE )--RIBOMIC Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced that the Eye has published full results from the phase 1 (SUSHI) and phase 2 (TOFU/RAMEN/TEMPURA) trials evaluating the efficacy and safety of intravitreal umedaptanib pegol in nAMD 1,2 . TOFU is a randomized, double-masked study assessing the efficacy of intravitreal umedaptanib pegol monotherapy or in combination with Eylea®, compared to Eylea® monotherapy in 86 subjects with anti-VEGF pretreated nAMD. RAMEN is an extension study of TOFU, in which 22 subjects who had exited the TOFU study received 4 monthly intravitreal injections of umedaptanib pegol. TEMPURA is an investigator-sponsored, single-center, open-label, 4-month study of umedaptanib pegol in five treatment-naïve nAMD patients. Throughout these studies umedaptanib pegol was safe, well tolerated, and effective to treat nAMD patients with no or short history of anti-VEGF treatment. Striking improvements in visual acuity and anatomy were observed in some of the treatment naïve patients. In nAMD patients with a long history of anti-VEGF treatment, umedaptanib pegol showed no additional benefit of monotherapy or the combination over Eylea®. Nevertheless, the pre-existing fibrosis remained stable without worsening in these studies. Notably, visual acuity decreased slightly in patients who switched from anti-VEGF (Eylea®) to umedaptanib pegol in the RAMEN study. Therefore, we believe that umedaptanib pegol is an excellent alternative as a first-line medication before patients are exposed to anti-VEGF treatments to mitigate risk of damage caused by fibrosis. Further studies are needed on the efficacy of umedaptanib pegol early in the onset of nAMD as well as in coordination or combination with anti-VEGF drugs. “We are very pleased that The Royal College of Ophthalmologists journal ( Eye ) recognized the trial results as a viable Proof-of-Concept for umedaptanib pegol in nAMD therapy. This first clinical evidence is an exciting breakthrough which raises hope that a non-VEGF target can lead to successful monotherapy in nAMD and provide a first-line alternative to treatment naïve nAMD patients.” commented Yoshi Nakamura, Ph.D., the CEO of RIBOMIC Inc. References 1 Pereira, D.S., Akita, K., Bhisitkul, R.B., Nishihata, T., Ali, Y., Nakamura, E., Nakamura, Y.: Safety and tolerability of intravitreal umedaptanib pegol (anti-FGF2) for neovascular age-related macular degeneration (nAMD): a phase 1, open label study. Eye, published online: 01 December 2023. URL: https://www.nature.com/articles/s41433-023-02849-6.pdf 2 Pereira, D.S., Maturi, R.K., Akita, K., Bhisitkul, R.B., Nishihata, T., Sakota, E., Ali, Y., Nakamura, E., Bezwada, P., Nakamura, Y.: Clinical proof of concept for anti-FGF2 therapy in exudative age-related macular degeneration (nAMD): phase 2 trials in treatment-naïve and anti-VEGF pretreated patients. Eye, published online: 30 November 2023. URL: https://www.nature.com/articles/s41433-023-02848-7.pdf About Umedaptanib Pegol Umedaptanib pegol is a novel oligonucleotide-based aptamer formerly called RBM-007 with potent anti-FGF2 (fibroblast growth factor 2) activity. FGF2 is implicated in not only angiogenesis but also fibrosis in several diseases including nAMD. The dual action of umedaptanib pegol (anti-angiogenic and anti-scarring) holds promise as an additive or alternative therapy to anti-VEGF treatments for nAMD. The three completed Phase 2 studies in nAMD are: 1. Active-controlled, double masked trial, TOFU study (NCT04200248); 2. Single-arm, open-label extension trial, RAMEN (NCT04640272); and 3. Investigator sponsored trial with treatment naïve nAMD patients, the TEMPURA study (NCT04895293). About Exudative Age-Related Macular Degeneration Exudative age-related macular degeneration (nAMD), is the leading cause of blindness in the United States and Europe. It is caused by the formation of abnormal and leaky new blood vessels under the retina, termed choroidal neovascularization. The leakage of fluid from the vessels causes retinal thickening and retinal degeneration including fibrotic scar formation, and leads to severe and rapid loss of vision. ABOUT RIBOMIC RIBOMIC is a clinical stage bio-pharmaceutical company specializing in the discovery and development of aptamer therapeutics, which is one type of nucleic acid medicine, a field with much potential for the development of next-generation drugs. The RiboART system, the company’s core drug discovery platform, can be used for the discovery of many types of aptamer drugs. RIBOMIC is dedicated to the discovery and development of drugs that target the broad field of unmet medical needs, which encompasses eye disorders, rare disease of short stature in children and many other diseases. See RIBOMIC website for more information. https://www.ribomic.com/eng/ Forward-Looking Statements This announcement contains forward-looking statements relating to current plans, estimates, strategies, belief and the future performance of Company. These statements are based on Company’s current expectations in light of the information and assumptions currently available so that Company does not promise the realization and these expectations may differ materially from those discussed in the forward-looking statements. These factors include, but not limited to, i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, ii) currency exchange rate fluctuations, iii) claims and concerns on the product safety and efficacy, iv) completion and discontinuation of clinical trials, v) infringement of Company’s intellectual property rights by third parties. Information on pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice. "RIBOMIC," "RiboART system" and the RIBOMIC logo are registered trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.

导 读RNA疗法是一种使用基于RNA分子来治疗或预防特定疾病的新疗法。随着mRNA COVID-19疫苗获得紧急授权并正式投入使用，RNA药物成为了研发新热点。纯化和细胞传递方面的进步使mRNA疗法得以广泛应用。与传统药物相比，RNA疗法具有成本效益高、易生产等优势。目前主要的 RNA 疗法包括：反义寡核苷酸、小干扰RNA（siRNA）、mRNA以及核酸适配体。本文将利用IQVIA Pipeline Intelligence数据库，回顾RNA疗法的最新进展。1RNA疗法在肿瘤治疗中的运用随着科学家对以寡核苷酸或siRNA为基础的靶向非编码RNA展现出越来越多的兴趣，RNA疗法在癌症领域的探索再度兴起。非编码RNA的优势在于其具有肿瘤特异性，即只在肿瘤中具有活性。Sirnaomics的cotsiranib (STP 705)是一种抑制TGF-Beta1和COX-2基因表达的双重靶点siRNA治疗方法，用于非黑色素瘤皮肤癌，包括鳞状细胞癌，基底细胞癌和肝癌的治疗。2022年2月，Sirnaomics公布了cotsiranib治疗皮肤基底细胞癌II期临床试验的中期数据。数据显示，剂量范围在30至90微克之间的患者，其剂量反应实现了完全应答，且无明显的皮肤不良反应。研发人员也在积极探索将mRNA疫苗技术应用于癌症的治疗干预，并设计为肿瘤相关抗原的表达，用于诱导细胞介导的免疫反应，以摧毁癌细胞。目前有两种mRNA疫苗正处于Ⅱ期临床试验阶段。默克和Moderna合作研发的mRNA 4157是一种基于mRNA的个性化癌症疫苗，通过引导患者的细胞表达选定的新表位，刺激免疫系统更好地识别并消灭癌细胞。该疫苗正处于Ⅱ期临床试验，验证与pembrolizumab联合用于治疗高风险的黑色素瘤患者，预计将于2023年12月完成。基因泰克和BioNTech研发的基于mRNA的个体化癌症疫苗autogene cevumeran（RG 6180；BNT 122）编码了20个来自患者的特异性肿瘤新抗原，以诱导针对肿瘤的强大免疫反应。该疫苗正作为一线治疗药物与pembrolizumab联合使用，对未经治疗的晚期黑色素瘤患者进行II期临床试验。同时，对将其作为替代II期（高风险）或III期手术切除结直肠癌的治疗模式的II期试验正在进行中。2RNA疗法在传染性疾病治疗中的运用BioNTech/辉瑞和Moderna的COVID-19疫苗是最早进入市场的两种mRNA疫苗。2020年12月11日，美国FDA紧急授权使用辉瑞和BioNTech共同研发的mRNA新冠疫苗tozinameran。Tozinameran采用LNP递送技术，由编码SARS-CoV-2的突变针刺蛋白的核苷修饰的mRNA组成，并于2021年8月23日被FDA正式批准用于预防16岁及以上人群的新冠肺炎。该疫苗随后在全球范围获得了100多个监管机构的批准。Moderna公司的elasomeran（SPIKEVAX；mRNA 1273）是一种由脂质纳米粒子包裹的RNA链组成的mRNA疫苗，编码一种预融合稳定形势的刺突SARS-CoV-2蛋白，已在美国、英国、欧盟、澳大利亚、加拿大、韩国和瑞士获批用于预防18岁及以上人群的新冠肺炎。该疫苗获得了韩国的附条件批准，并获得了多个国家的紧急使用授权，包括美国、日本和印度。3RNA疗法在心血管代谢性疾病治疗中的应用在过去十年中，研究人员已发现，部分RNA有助于调控心血管疾病，抑制胆固醇的形成、胆固醇斑块的堆积和心脏病发作后导致的细胞死亡。RNA疗法正作为一种治疗心血管代谢疾病的方法迅速崛起。Alnylam公司的patisiran（ONPATTRO）是一种针对转甲状腺素（TTR）的RNAi疗法，利用Arbutus公司专有的脂质纳米粒子技术，是第一个获得美国FDA批准的RNAi疗法，于2018年上市，用于治疗遗传性转甲状腺素介导的（hATTR）淀粉样变性引起的多发性神经病。Patisiran旨在通过抑制TTR蛋白的合成来使TTR mRNA沉默，并防止TTR淀粉样蛋白在组织中进一步积累。Patisiran也已在加拿大、欧盟和巴西获得批准。4RNA疗法在眼科疾病领域的应用眼科疾病领域是RNA疗法的另一个发展领域，基因沉默疗法在该领域中显示出良好表现。ProQR的ultevursen (QR 421a)是一种基于RNA的寡核苷酸药物，旨在治疗USH2A基因13号外显子突变引起的Usher综合征Ⅱ型和非综合征性视网膜色素变性。Ultevursen与突变的USH2A RNA结合，并通过外显子跳转方法将13号外显子从RNA中排除，使视网膜细胞能够产生一种略微缩短但功能正常、且对视觉至关重要的usherin蛋白的表达。目前，针对这些适应症的II/III期临床试验正在进行中。此外，还有两个项目的Ⅱ期试验也在进行中。Ionis的IONIS-FB-LRx是一种使用Ionis LICA技术设计的反义药物，旨在减少补体先天免疫系统中的关键蛋白补体因子B的产生。Ribomic的RBM 007是一种基于寡核苷酸的抗FGF2（成纤维细胞生长因子2）适体，能够同时抑制血管生成及视网膜中的瘢痕形成。 总 结 RNA疗法已成为治疗多种疾病的有效方式，为靶向致病基因表达模式提供了更多选择，具有可高效生产、可提供长期疗效，可降低基因毒性风险的特点，2020年首次获批用于预防COVID-19的mRNA疫苗就是一个成功案例。技术创新有助于扩大RNA疗法的应用范围，推进mRNA等复杂核酸模板的使用，造福更多患者。